Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | AXA Investment Managers S.A. |
Company dealt in | Applegreen PLC |
Class of relevant security to which the dealings being disclosed relate (Note 2) | € 0.01 ordinary shares |
Date of dealing | 14th January 2021 |
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 2,643,750 (2.19%) | |||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | 2,643,750 (2.19%) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) |
||||||
(3) Options and agreements to purchase/sell |
||||||
Total |
Ap20
Purchase/sale |
Number of relevant securities |
Price per unit (Note 5) |
Sale | 200,000 | GBP 5.04 |
(b) Derivatives transactions (other than options transactions)
Product name,
e.g. CFD |
Nature of transaction
(Note 6) |
Number of relevant securities
(Note 7) |
Price per unit
(Note 5) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
(ii) Exercising
Product name,
e.g. call option |
Number of securities | Exercise price per unit (Note 5) |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction
(Note 8) |
Details | Price per unit
(if applicable) (Note 5) |
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 15th January 2021 |
Contact name | Victoria Warmé |
Telephone number | +33 (0) 1 44 45 83 60 |
If a connected EFM, name of offeree/offeror with which connected | |
If a connected EFM, state nature of connection (Note 10) |
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | AXA Investment Managers S.A. |
Company dealt in | Applegreen PLC |
Class of relevant security to which the dealings being disclosed relate (Note 2) | € 0.01 ordinary shares |
Date of dealing | 14th January 2021 |
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 2,643,750 (2.19%) | |||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | 2,643,750 (2.19%) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) |
||||||
(3) Options and agreements to purchase/sell |
||||||
Total |
Ap20
Purchase/sale |
Number of relevant securities |
Price per unit (Note 5) |
Sale | 2,000,000 | GBP 5.04 |
(b) Derivatives transactions (other than options transactions)
Product name,
e.g. CFD |
Nature of transaction
(Note 6) |
Number of relevant securities
(Note 7) |
Price per unit
(Note 5) |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
(ii) Exercising
Product name,
e.g. call option |
Number of securities | Exercise price per unit (Note 5) |
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction
(Note 8) |
Details | Price per unit
(if applicable) (Note 5) |
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 18th January 2021 |
Contact name | Victoria Warmé |
Telephone number | +33 (0) 1 44 45 83 60 |
If a connected EFM, name of offeree/offeror with which connected | |
If a connected EFM, state nature of connection (Note 10) |
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP)…
WALLINGFORD, Conn., June 18, 2024 /PRNewswire/ -- InsiteOne, a leading provider of cloud-based Vendor Neutral Archive…
BETHLEHEM, Pa., June 18, 2024 /PRNewswire/ -- Young Women's Christian Association of Bethlehem PA ("YWCA…
Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead…
Combined entity delivers the ICyte® revenue optimization platform powered by first-party data, AI-enabled data exploration,…
CHICAGO, June 18, 2024 /PRNewswire/ -- WellBe Senior Medical and its affiliated medical groups announce…